Alligator Bioscience Q3 2023: Awaiting the OPTIMIZE-1 Results - Redeye

Redeye comments on Alligator’s Q3 report. The OPTIMIZE-1 topline readout will be a major catalyst and is expected in early Q1 2024. The costs were lower in and cash flow better in Q3 than in Q2, leaving the company with a cash and cash equivalents position of SEK124m.

Länk till analysen i sin helhet: https://www.redeye.se/research/951277/alligator-bioscience-q3-2023-awaiting-the-optimize-1-results?utm_source=finwire&utm_medium=RSS